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Abstract
Background: Mutations in Leucine-rich repeat kinase 2 NM_198578 (LRRK2 c.6055G > A (p.G2019S), LRRK2 c.
4321C > G (p.R1441G)) and alpha-synuclein NM_000345 (SNCA c.209G > A (p.A53T)) genes causing Parkinson’s
disease (PD) are common in Mediterranean populations. Variants in the Quinoid Dihydropteridine Reductase
NM_000320 (QDPR c.68G > A (p.G23D)), Sepiapterin Reductase NM_003124 (SPR c.596-2A > G) and
Methylenetetrahydrofolate Reductase NM_005957 (MTHFR c.677C > T and c.1298A > C) genes are frequent
in Malta and potential candidates for PD.
Methods: 178 cases and 402 control samples from Malta collected as part of the Geoparkinson project were
genotyped for MTHFR polymorphisms, QDPR and SPR mutations. Only PD and parkinsonism cases were tested
for SNCA and LRRK2 mutations.
Results: LRRK2 c.4321C > G and SNCA c.209G > A were not detected. The LRRK2 c.6055G > A mutation was found
in 3.1 % of Maltese PD cases. The QDPR mutation was found in both cases and controls and did not increase risk
for PD. The SPR mutation was found in controls only. The odds ratios for MTHFR polymorphisms were not
elevated.
Conclusions: The LRRK2 c.6055G > A is a cause of PD in the Maltese, whilst QDPR c.68G > A, SPR c.596-2A > G and
MTHFR c.677C > T and c.1298A > C are not important determinants of PD.
Keywords: Quinoid Dihydropteridine Reductase, Sepiapterin Reductase, Methylenetetrahydrofolate Reductase,
Leucine-rich repeat kinase 2, Alpha-synuclein, Parkinson’s Disease, Maltese
Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterised by motor and non-motor symptoms and
loss of dopaminergic neurons. A number of candidate
genes were investigated to uncover the PD causing muta-
tions in the Maltese population. Mutations in leucine-rich
repeat kinase 2 NM_198578 (LRRK2) and alpha-synuclein
NM_000345 (SNCA) genes have been associated with
PD. Three mutations in these genes, namely LRRK2
c.6055G > A, LRRK2 c.4321C > G and SNCA c.209G > A
are pathogenic mutations found in Mediterranean pop-
ulations [1]. The Quinoid Dihydropteridine Reductase
NM_000320 (QDPR) c.68G > A mutation and Sepiap-
terin Reductase NM_003124 (SPR) c.596-2A > G splice
variant, are autosomal recessive mutations known to
cause dihydropteridine reductase (DHPR) deficiency
and Dopa-Responsive Dystonia (DRD) respectively in
the Maltese with a high carrier frequency compared to
other populations [2]. Catecholamine synthesis in pa-
tients is impaired as tetrahydrobiopterin (BH4), an es-
sential cofactor of aromatic amino acid hydroxylases, is
not produced in sufficient amounts as a result of these
mutations [3]. SR is involved in de novo BH4 synthesis
whilst DHPR is involved in recycling of the reduced
cofactor [4]. It has been suggested that the SPR gene is
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the PARK3 locus implicated in sporadic PD [1] and de-
creased activity of DHPR due to low biopterin levels
causes PD [5]. DHPR deficiency and DRD and PD have
symptoms in common. The latter is characterized by
childhood-onset dystonia responding well to low doses
of L-Dopa. Gait and posture abnormalities are observed
as the legs are primarily affected with diurnal fluctuation.
Symptoms of parkinsonism (PS) are common. DHPR
deficiency also presents with tonic disorders, abnormal
movements, psychomotor retardation, hypersalivation and
drooling, swallowing difficulties, hyperthermia [3, 6].
There is evidence that both the SPR and QDPR genes are
good candidates to test for associations for PD.
MTHFR reduces folate and is involved in the production
of S-adenosylmethionine which plays a role in dopamine
(DA) synthesis and metabolism [7]. Defective MTHFR
enzyme due to MTHFR NM_005957 c.1298A > C and
c.677C > T has a lower activity and may result in elevated
homocysteine levels, found to be relatively high in sera of
PD patients [7, 8]. An indirect connection between the
BH4 and folate pathways has been postulated [9]. The
MTHFR c.677C > T TT genotype is found at a frequency
of 9.1 % in Maltese newborn [10]. The mutant allele
frequency for the MTHFR c.1298A > C was reported to be
23.2 % [11].
The objective of this study was to establish whether
known pathogenic mutations (LRRK2 c.6055G > A, LRRK2
c.4321C >G and SNCA c.209G >A) are present in Maltese
PD and PS cases, and to determine whether the functional
MTHFR c.677C > T and c.1298A > C, QDPR c.68G >A
and SPR c.596-2A >G genetic variants alter susceptibility
to PD. This is the first time these genes have been tested
for involvement in PD in the Maltese population.
Methods
Altogether 178 cases and 402 controls (Table 1) from
Malta were collected as part of the FP5 EU-funded
Geoparkinson project [12, 13]. The collection and test-
ing were approved by the Research Ethics Committee of
the University of Malta, Approval Numbers 53/2002 and
52/2008. All participants gave written informed consent.
Cases were classified as having PD or PS using the
United Kingdom Parkinson’s Disease Society Brain Bank
clinical diagnostic criteria. Controls did not have PD or
PS and were recruited from the community and from
the bleeding room at St Luke’s Hospital which served
many outpatient departments.
Genotyping of the QDPR c.68G > A, SPR c.596-2A > G
[2], MTHFR c.677C > T [14], LRRK2 c.6055G > A [15],
LRRK2 c.4321C > G [16] and SNCA c.209G > A [17] was
performed as described previously. Genotyping of the
MTHFR c.1298A > C was done using the 5’ exonuclease
assay [18]. Cases and controls were genotyped for the
QDPR c.68G > A, SPR c.596-2A > G mutations and the
MTHFR c.677C > T and c.1298A > C polymorphisms.
Genotyping for the LRRK2 c.6055G > A, LRRK2
c.4321C > G and SNCA c.209G > A was limited to cases
since these are known PD-causing mutations [1].
DNA of 79 controls and 27 cases collected as part of
the Geoparkinson project had been used up. These were
mainly buccal samples. Additionally the PCRs did not
work in a few samples.
Data Analysis: Allele frequencies were calculated. The
genotypes in controls, when available, were tested for con-
formity with the Hardy-Weinberg Equilibrium (HWE).
Both the crude and adjusted odds ratios (ORs) were calcu-
lated and the 95 % confidence intervals (CI) were derived
from the logistic regression model.
Results
Four cases were heterozygous for the LRRK2 c.6055G >
A mutation, giving an allele frequency of 1.4 % in PD
and PS cases. This frequency was 3.1 % in PD cases
alone. All were males with no family history of disease.
Data for age at diagnosis was only available for two
cases, one with PD and one with PS, both diagnosed at
65 years of age. None of the cases had the LRRK2
c.4321C > G or SNCA c.209G > A mutations. The fre-
quencies obtained for the variants studied are presented
in Tables 2 and 3.
Odds ratios for combined PD and PS cases were OR 0.9
(95 % CI 0.5–1.6) for the MTHFR 677 TT and 1.2 (95 %
CI 0.6–2.1) for the MTHFR 1298 CC genotypes respect-
ively. The results did not change materially after restrict-
ing to cases with PD or PS (see Additional file 1). No
deviations from HWE were observed.
Table 1 Characteristics of the population studied
Characteristics Cases
(N = 178)
Controls
(N = 402)
Mean age (range) 72.9 (41–91) 74.3 (41–95)
Mean age of diagnosisa 66.3 (35–90)
Males 110 (61.8 %) 224 (55.7 %)
Females 68 (39.2 %) 178 (44.3 %)
Parkinson’s Disease 118
Parkinsonism 60
% Parkinsonism 33.70 %
Smokersd 61 (34.3 %) 177 (44.0 %)
Ever knocked unconsciouse 33b (18.6 %) 48 (11.9 %)
Family history of Parkinson’s diseasee 35 (19.7 %) 16c (4.0 %)
Use of pesticidese 27 (15.2 %) 42 (10.4 %)
aOut of 135 cases for which this data was available
bOut of 177 cases
cOut of 401 controls
dAssociated with decreased risk for PD and PS
eAssociated with increased risk for PD and PS
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The allele frequency for QDPR c.68G > A was 0.3 % in
both cases and controls. Two controls and one case were
heterozygous for QDPR c.68G > A. One control was a
73 year old male whilst the other control was a 66 year
old female. The case identified fulfilled the criteria for
PD. She was 53 years of age when diagnosed and was
also heterozygous for the MTHFR c.1298A > C poly-
morphism. None had a family history of PD.
Four individuals were identified as carriers of SPR
c.596-2A > G, all of which were controls giving an allele
frequency of 0.7 %. One was female aged 70, whilst the
others were all men with ages of 79, 49 and 66.
Discussion
The known disease-causing LRRK2 c.6055G >A mutation
was detected in PD cases whereas the LRRK2 c.4321C >G
and SNCA c.209G >A mutations were not detected. The al-
lele frequency of QDPR c.68G >A was the same in the cases
and the controls whilst SPR c.596-2A >G was not detected
in cases. The MTHFR c.677C >T and MTHFR c.1298A >C
polymorphisms were not associated with PD in this study.
Four cases were heterozygous for the LRRK2
c.6055G > A mutation giving an allele frequency of
1.4 % in PD and PS cases or 3.1 % in PD cases alone.
LRRK2 (c.4321C > G and c.6055G > A) mutations cause
amino acid changes within the GTPase and/or kinase
domains respectively which may signify an enzymatic
change and thus mediate LRRK2 pathogenesis [19, 20].
The frequency of LRRK2 c.6055G > A was estimated to
be 1 % of patients with sporadic PD and 4 % of patients
with hereditary PD in other populations, with the high-
est frequencies occurring in Arabs and Jews but is rare
in Asia [21]. This may be explained by differences in
descent and founder effects [22]. The frequency of this
mutation in Maltese PD patients, 3.1 %, is similar to that
in the Spanish, Italians and Sardinians [21]. This is the
first report of this mutation being found in the Maltese.
The LRRK2 c.4321C > G is common in the Basque
population [23, 24]. The SNCA c.209G > A mutation is
thought to have arisen from a common founder with
Mediterranean ancestry [25, 26]. The results of the
present study indicate that the LRRK2 c.4321C > G and
Table 2 Allele Frequencies for the variants studied
Mutation/polymorphism Allele frequencies in %
Controls
(n mutant/total n)a
Cases
(n mutant/total n)a
QDPR c.68G > A 0.3 (2/612) 0.3 (1/300)
SPR c.596-2A > G 0.7 (4/594) 0.0 (0/296)
MTHFR c.677C > T 34.7 (216/622) 33.8 (102/302)
MTHFR c.1298A > C 35.9 (225/626) 37.7 (114/302)
Tested in cases only
LRRK2 c.6055G > A - 1.4 (4/292)
LRRK2 c.4321C > G - 0.0 (0/296)
SNCA c.209G > A - 0.0 (0/292)
n = number of alleles
aDNA of 79 controls and 27 cases had been used up and were therefore not
available and a few samples did not yield PCR products
Table 3 Genotype Frequencies for MTHFR, all cases (PD & PS)
Polymorphism Genotype frequencies p-value
MTHFR c.677C > T MTHFR c.1298A > C No. of Cases (%)a No. of Controls (%)a Age-adjusted OR (95 % CI)b
CC 66 (43.7) 136 (43.7) 1
CT 68 (45.0) 134 (43.1) 1.0 (0.7–1.6) 0.8
TT 17 (11.3) 41 (13.2) 0.9 (0.5–1.6) 0.6
AA 60 (39.7) 132 (42.2) 1
AC 68 (45.0) 137 (43.8) 1.1 (0.7–1.7) 0.7
CC 23 (15.2) 44 (14.1) 1.2 (0.6–2.1) 0.6
CC AA 16 (10.6) 24 (7.7) 1
CT AC 41 (27.2) 67 (21.6) 0.9 (0.4–2.0) 0.8
TT CC - - -
CC AC 27 (17.9) 69 (22.3) 0.6 (0.3–1.3) 0.2
CC CC 23 (15.2) 43 (13.9) 0.8 (0.4–1.8) 0.6
CT AA 27 (17.9) 66 (21.3) 0.6 (0.3–1.3) 0.2
CT CC - - -
TT AA 17 (11.3) 41 (13.2) 0.6 (0.3–1.5) 0.3
TT AC - - -
aDNA of 79 controls and 27 cases had been used up and were therefore not available and a few samples did not yield PCR products
bp-values were all >0.05
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SNCA c.209G > A mutations are very rare or completely
absent in the Maltese population.
The allele frequencies for the QDPR c.68G > A and
SPR c.596-2A > G we observed in controls (0.3 % and
0.7 % respectively) are much lower than those reported
previously (3.3 % and 4.6 % tested on 272 and 87
newborns respectively) [2]. Therefore, we tested the
population frequency in a larger number of Maltese
newborn and observed allele frequencies of 0.64 %, and
1.3 % for the QDPR and SPR polymorphisms respectively
(N= 475 and 315 respectively). These mutations are not
a major cause of PD in the Maltese.
MTHFR was not a contributor to PD. The genotype
frequencies obtained for the MTHFR c.677C > T are
43.7 % CC, 43.1 % CT and 13.2 % TT which are compar-
able to others reported for Maltese newborn [10, 27]. In
contrast, the mutant allele frequency for the MTHFR
c.1298A > C was somewhat higher than that observed
previously in Maltese newborn (35.9 % vs. 23.2 % [11]).
This suggests that there is no clear effect of these SNPs
on PD probably due to the complex pathways involved.
The c.677C > T and c.1298A > C prevalence and fre-
quencies vary considerably with ethnicities and geography
[7]. While some studies have reported a lack of association
between MTHFR polymorphisms and PD [28], others [29]
reported a higher frequency of the MTHFR 677 TT geno-
type in PD patients and controls.
The MTHFR c.667C > T dimorphism causes hyperho-
mocysteimia in folate deficient individuals [30]. Homo-
zygous mutants for MTHFR c.1298A > C have a lower
enzyme activity than homozygous wildtype [7]. It is pos-
sible that the Maltese diet includes sufficient folate
levels. In fact only 1.5 % of adult Maltese women and
3.1 % of adult Maltese men had low serum folate levels
in a group of population controls and 1.5 % of women
and 1.2 % of men had low serum Vitamin B12 levels
(N = 137 and N = 326 for women and men respectively;
Attard R and Bezzina Wettinger S, unpublished obser-
vations). The chance of being heterozygous or homozy-
gous for these polymorphisms with low folate status is
therefore very low. It should be noted that higher nutri-
ent intake (folate and B vitamins) did not lower PD risk
in a previous study [31]. It cannot be excluded that
these polymorphisms have an effect in populations or
individuals with low folate and Vitamin B12 levels.
This study had 80 % power to detect a 2-fold increase
in risk for the MTHFR polymorphisms (35 % allele fre-
quency), a 5-fold increased risk for SPR c.596-2A > G
(0.7 % allele frequency) and an 8-fold increased risk for
QDPR c.68G > A (0.3 % allele frequency) assuming a
dominant model and for the MTHFR polymorphisms
the sample size was sufficient to detect a two-fold in-
crease in risk even for a recessive model assuming up to
a 5 % Type I error rate. Thus the study is sufficiently
powered to exclude a strong effect on PD risk of the
SPR and QDPR mutations, and even 2-fold or more in-
crease in risk due to the MTHFR mutations.
Conclusion
The LRRK2 c.6055G > A mutation accounts for 3.1 % of
PD in the Maltese population. As LRRK2 c.6055G >A ex-
hibits low penetrance and is found occasionally in controls
[21], testing for LRRK2 c.6055G >A may be performed on
patients and relatives who wish to ascertain the presence
of a genetic defect. Testing for LRRK2 c.4321C >G and
SNCA c.209G > A are not recommended as a first line of
genetic testing in Maltese PD patients. There is no evi-
dence to support involvement of DHPR and SR in PD, at
least alone. One cannot exclude that they have a weak ef-
fect and even possibly an interaction when found together
with other mild mutations. The absence of the LRRK2
c.4321C >G and SNCA c.209G >A could be a result of
historical bottlenecks, and there may be some founder
mutation in the Maltese that may explain familial cases
that has not yet been tested for.
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